Paul Matteis
Stock Analyst at Stifel
(1.93)
# 3,068
Out of 4,944 analysts
109
Total ratings
38.36%
Success rate
-9.02%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $494 → $455 | $387.77 | +17.34% | 19 | Aug 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $166 → $174 | $128.89 | +35.00% | 9 | Jul 31, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $66 → $36 | $11.64 | +209.41% | 4 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $96.39 | -2.48% | 2 | May 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $429.93 | -19.75% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $1.50 | +33.33% | 2 | Mar 7, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $21.03 | +52.16% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $12.14 | +163.59% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $4.22 | +160.66% | 1 | Feb 27, 2025 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $14.30 | +123.78% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.00 | +100.00% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $3.18 | +214.47% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $19.17 | +212.99% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $27.43 | +31.24% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $56.86 | +53.01% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $15.54 | +125.23% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $41.41 | +27.99% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $25.45 | -17.49% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $6.75 | +329.63% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $128.93 | +122.60% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.67 | +328.27% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.86 | +319.58% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.14 | +2,005.26% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.39 | +1,195.34% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $12.25 | +161.22% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.26 | +2,042.86% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $13.40 | +4.48% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $8.45 | +657.40% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $62.00 | +448.39% | 1 | Dec 21, 2016 |
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Hold
Price Target: $494 → $455
Current: $387.77
Upside: +17.34%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Buy
Price Target: $166 → $174
Current: $128.89
Upside: +35.00%
Dyne Therapeutics
Jul 31, 2025
Maintains: Buy
Price Target: $66 → $36
Current: $11.64
Upside: +209.41%
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $96.39
Upside: -2.48%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $429.93
Upside: -19.75%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $1.50
Upside: +33.33%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $21.03
Upside: +52.16%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $12.14
Upside: +163.59%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $4.22
Upside: +160.66%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $14.30
Upside: +123.78%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.00
Upside: +100.00%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.18
Upside: +214.47%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $19.17
Upside: +212.99%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $27.43
Upside: +31.24%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $56.86
Upside: +53.01%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $15.54
Upside: +125.23%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $41.41
Upside: +27.99%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $25.45
Upside: -17.49%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $6.75
Upside: +329.63%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $128.93
Upside: +122.60%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $4.67
Upside: +328.27%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.86
Upside: +319.58%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.14
Upside: +2,005.26%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.39
Upside: +1,195.34%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $12.25
Upside: +161.22%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.26
Upside: +2,042.86%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $13.40
Upside: +4.48%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $8.45
Upside: +657.40%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $62.00
Upside: +448.39%